JeffreyJCrowleyMD

PubMed

• Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) vers...
  Gooderham, M., Vender, R., Hong, H., Feely, M., Garrelts, A., See, K., Konicek, B., Crowley, J., Green, L.> ;Dermatology and Therapy. 2024 Feb 1
• Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestation...
  Bruce Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda Gooderham, Alan Menter, Robert Strohal, Michael M Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Phot...> ;Journal of the European Academy of Dermatology and Venereology. 2024 May 1
• 3 citations
  Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
  Andrew Blauvelt, Diamant Thaçi, Kim A Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Daphne Chan, Jenny Yu, Ya-Wen Yang, M...> ;The British Journal of Dermatology. 2023 Jul 7
• 1 citations
  Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
  Bruce Strober, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu, Huzefa Photowala, Jeffrey Crowley> ;The Journal of Dermatological Treatment. 2022 Nov 1
• 8 citations
  Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
  Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, Andreas Pinter, Laura K Ferris, Simone Rubant, Huzefa Photowala, Zhenyi Xue, Tianshuang Wu, Tianyu Zhan, Stefan...> ;Dermatology and Therapy. 2022 Feb 1
• 16 citations
  A brief guide to pustular psoriasis for primary care providers.
  Jeffrey J Crowley, David M. Pariser, Paul S. Yamauchi> ;Postgraduate Medicine. 2021 Apr 3
• 6 citations
  Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
  Boni E. Elewski, Alan Menter, Jeffrey J. Crowley, Stephen K. Tyring, Yang Zhao, Simon Lowry, Stephen J. Rozzo, Alan M. Mendelsohn, J. Parno, Kenneth B. Gordon> ;The Journal of Dermatological Treatment. 2020 Nov 16
• 36 citations
  A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, dou...
  A Blauvelt, C Leonardi, B Elewski, J J Crowley, L C Guenther, M Gooderham, R G Langley, R Vender, A Pinter, C E M Griffiths, Y Tada, H Elmaraghy, R G Lima, G Gallo, L ...> ;The British Journal of Dermatology. 2021 Jun 1
• 36 citations
  A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a rand...
  A Blauvelt, K Papp, A Gottlieb, A Jarell, K Reich, C Maari, K B Gordon, L K Ferris, R G Langley, Y Tada, R G Lima, H Elmaraghy, G Gallo, L Renda, S Y Park, R Burge, J ...> ;The British Journal of Dermatology. 2020 Jun 1
• 2 citations
  Defining drug-free remission of skin disease in patients with plaque psoriasis.
  April W. Armstrong, Andrew Blauvelt, Jeffrey J. Crowley, Kenneth B. Gordon, Gerald G. Krueger, James G. Krueger, Jeffrey M. Sobell, Bruce Strober, Bhaskar Srivastava, ...> ;The British Journal of Dermatology. 2020 Jun 1
• 14 citations
  Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
  Kenneth B. Gordon, Kristian Reich, Jeffrey J. Crowley, Neil J. Korman, F T Murphy, Yves Poulin, Lynda Spelman, Paul S. Yamauchi, Alan M. Mendelsohn, J. Parno, Stephen ...> ;The Journal of Dermatological Treatment. 2020 Apr 30
• 11 citations
  Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice
  Alexa B. Kimball, Jeffrey J. Crowley, Kim Papp, Brian M. Calimlim, Yinghui Duan, A.B. Fleischer, Jeffrey M. Sobell> ;Journal of the European Academy of Dermatology and Venereology. 2020 Mar 1
• 18 citations
  Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
  Boni E. Elewski, C.S. Baker, Jeffrey J. Crowley, Yves Poulin, Martin M. Okun, B. Calimlim, Ziqian Geng, O. Reyes Servin, Phoebe Rich> ;Journal of the European Academy of Dermatology and Venereology. 2019 Nov 1
• 161 citations
  Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 ...
  Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J. Crowley, Caitriona Ryan, James G. Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A. Williams, Elizab...> ;Lancet. 2019 Aug 17
• 50 citations
  Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
  Jeffrey J. Crowley, Richard B. Warren, Jennifer Clay Cather> ;Journal of the European Academy of Dermatology and Venereology. 2019 Jun 27
• 10 citations
  Systematic review of the real-world evidence of adalimumab safety in psoriasis registries.
  Bruce Strober, Jeffrey J. Crowley, Richard G. Langley, Kenneth B. Gordon, Alan Menter, C. Leonardi, Dilek Arikan, Wendell C. Valdecantos> ;Journal of the European Academy of Dermatology and Venereology. 2018 Dec 1
• 12 citations
  Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab
  Andrew Blauvelt, Talia M. Muram, Kyoungah See, Craig H. Mallinckrodt, Jeffrey J. Crowley, Peter C.M. van de Kerkhof> ;The Journal of Dermatological Treatment. 2018 Apr 3
• 7 citations
  Biosimilars: what the dermatologist should know.
  Paul S. Yamauchi, Jeffrey J. Crowley, P. Kaur, Lynda Spelman, Richard B. Warren> ;Journal of the European Academy of Dermatology and Venereology. 2018 Feb 19
• 54 citations
  Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
  Boni E. Elewski, Martin M. Okun, Kim A. Papp, Christopher M. Baker, Jeffrey J. Crowley, Gérard Guillet, Yves Poulin, Yihua Gu, Ziqian Geng, David A. Williams, Phoebe R...> ;Journal of the American Academy of Dermatology. 2018 Jan 1
• 122 citations
  Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM...
  Jeffrey J. Crowley, Diamant Thaçi, Pascal Joly, Ketty Peris, Kim A. Papp, Joana Carla Soares Gonçalves, Robert M. Day, Rongdean Chen, K. Shah, Carlos Ferrándiz, Jennif...> ;Journal of the American Academy of Dermatology. 2017 Aug 1
• 182 citations
  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
  Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, C. Birbara, Janusz Jaworski, Jacob A. Aelion, R. Stevens, Adele R. Vessey, Xiaojiang Zhan, Paul Bird> ;Annals of the Rheumatic Diseases. 2016 Jun 1
• 99 citations
  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (...
  Phoebe Rich, Melinda Gooderham, Hervé Bachelez, Joana Carla Soares Gonçalves, Robert M. Day, Rongdean Chen, Jeffrey J. Crowley> ;Journal of the American Academy of Dermatology. 2016 Jan 1
• 293 citations
  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized c...
  Carle Paul, J. Cather, Melinda Gooderham, Yves Poulin, Ulrich Mrowietz, Carlos Ferrándiz, Jeffrey J. Crowley, C. Hu, Rm Stevens, K. Shah, Rm Day, Giampiero Girolomoni,...> ;The British Journal of Dermatology. 2015 Dec 1
• 570 citations
  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
  Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Weglowska, Lluís Puig, Kim A. Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Arms...> ;The New England Journal of Medicine. 2015 Sep 30
• 67 citations
  Treatment of Nail Psoriasis: Best Practice Recommendations From the Medical Board of the National Psoriasis Foundation
  Jeffrey J. Crowley, Jeffrey M Weinberg, Jashin J. Wu, Andrew D. Robertson, Abby S. Van Voorhees> ;JAMA Dermatology. 2015 Jan 1
• Join now to see all